Apoptosis in multiple myeloma: Therapeutic implications

Apoptosis

Volumn 6, Issue 1-2, 2001, Pages 47-55

  Chauhan, D ^a   Anderson, K C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Apoptosis; Multiple myeloma; Signal transduction

Indexed keywords

ANGIOGENESIS INHIBITOR; IMMUNOMODULATING AGENT; THALIDOMIDE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; HUMAN; MULTIPLE MYELOMA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; MULTIPLE MYELOMA; SIGNAL TRANSDUCTION;

EID: 0035086995     PISSN: 13608185     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009620027205     Document Type: Review

References (85)

1. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics
2. Apoptosis-its significance in cancer and cancer therapy
3. Cell death: The significance of apoptosis
4. Apoptosis in the pathogenesis and treatment of disease
5. CD40 ligand triggers interleukin-6 mediated B cell differentiation
6. Response of purified myeloma cells to hematopoietic growth factors
7. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates IL-6 secretion
8. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kB
9. Transforming growth factor b1: Differential effects on multiple myeloma versus normal B cells
10. Advances in the biology of multiple myeloma: Therapeutic applications
11. Serum levels of interleukin-6, a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias
12. Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism
13. RAFTK/PYK2-dependent and independent apoptosis in multiple myeloma cells
14. Interleukin-6 inhibits apoptosis of malignant plasma cells
15. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
16. Cytokine signal transduction
17. Interleukin-6 family of cytokines and gp130
18. Interleukin-6 triggers cell growth via the ras-dependent mitogen-activated protein kinase cascade
19. Blockade of mitogen-activated protein kinase cascade signaling in interleukin-6 independent multiple myeloma cells
20. SH2-containing phosphotyrosine phosphatase as a target of protein-tyrosine kinases
21. Activation of a phosphotyrosine phosphatase by tyrosine phosphorylation
22. Recombinant interferon-gamma inhibits the growth of IL-6 dependent human multiple myeloma cell lines in vitro
23. Gamma-interferon in multiple myeloma: Inhibition of interleukin 6 dependent myeloma cell growth and downregulation of IL-6 receptor expression in vitro
24. Inhibitory effect of All-trans retinoic acid on the growth of freshly isolated myeloma cells via interference with interleukin-6 signal transduction
25. Disruption by interferon-gamma of autocrine IL-6 growth loop in IL-6 dependent U266 myeloma cells by homologous and heterologous downregulation of the IL-6 receptor alpha and beta chains
26. Functional interaction between retinoblastoma protein and stress activated protein kinase in multiple myeloma cells
27. Inhibition of acute lymphoblastic leukaemia by JAK-2 inhibitor
28. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
29. Interferon-gamma mediated activation of STAT-1 regulates growth-induced mitogenesis
30. STAT signaling in the pathogenesis and treatment of cancer
31. Constitutive activation of STA-3 signaling confers resistance to apoptosis in human U266 myeloma cells
32. Siganal tranducer and activator of transcription (STAT)-5 activation by Bcr-Abl is dependent on intact Src homology (SH3) and SH2 domains of Bcr-Abl, and is required for leukemogenesis
33. Targeted disruption of the mouse STAT-3 gene leads to early embryonic lethality
34. INK4A expression in multiple myeloma and plasma cell leukemia
35. MDM2 protein over-expression promotes proliferation and survival of multiple myeloma cells
36. Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of Retinoblastoma protein
37. WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-g in multiple myeloma cells
38. INK4A in interleukin-6-mediated growth of multiple myeloma
39. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells
40. Cytochrome-c dependent and independent induction of apoptosis in multiple myeloma cells
41. Interleukin-6 induced inhibition of multiple myeloma cell apoptosis: Support for the hypothesis that protection is mediated via inhibition of the JNK/SAPK pathway
42. Caspases: Enemies within
43. Apopain/CPP32 cleaves proteins that are essential for cellular repair A fundamental principle of apoptotic death
44. Proteolytic activation of protein kinase C-Delta by an ICE-Like protease in apototic cells
45. Mitochondria as regulator of apoptosis: Doubt no more
46. The novel retiniod 6-[3-(1-adamantyl]-2naphtalene carboxylic acid can trigger apoptosis through a mitochondrial pathway independent of the nucleus
47. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis
48. Prevention of apoptosis by Bcl-2-Release of Cytochrome-c from the mitochondria blocked
49. A lively meeting of a deathly topic
50. Identification and characterization of a novel related adhesion focal tyrosine kinase (RAFTK) from megakaryocytes and brain
51. Protein tyrosine kinase PYK2 involved in CA2+-induced regulation of ion channel and MAP kinase functions
52. Induction of apoptosis after expression of PYK2, a tyrosine kinase structurally related to focal adhesion kinase
53. Shp-2 tyrosine phosphatase: Signaling one cell or many
54. Protein tyrosine phosphatases in signal transduction
55. Protein tyrosine phosphatases in signaling
56. Genetic analysis of protein tyrosine phosphatases
57. Morophogenetic movements at gastrulation require the SH2 tyrosine phosphatase Shp2
58. The SHP-2 tyrosine phosphatase has opposite effects in mediating the activation of extracellular signal-regulated and c-jun NH2-terminal mitogen-activated protein kinases
59. Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4
60. Anti-estrogens induce apoptosis of multiple myeloma cells
61. Recombinant human TNF-related apoptosis inducing ligand (TRAIL) induces apoptosis of human multiple myeloma cells
62. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma
63. Angiogenesis in newly diagnosed multiple myeloma: Poor prognosis with increased microvessel density in bone marrow biopsies
64. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma
65. Anti-tumor activity of thalidomide in refractory multiple myeloma
66. Thalidomide alone or with dexamethasone for multiple myeloma
67. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade
68. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-a
69. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset
70. Expression of vascular endothelial growth factor and its receptor in hematological malignancies
71. The Proteosome inhibitor PS-341 in cancer therapy
72. Drug resistance in myeloma
73. Multidrug-resistant myeloma: Laboratory and clinical effects of verapamil as a chemosensitizer
74. Bcl-2 family of proteins
75. Dysregulation of apoptosis in cancer
76. Effects of Bcl-2 antisense oligodeoxenucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells
77. Role of NF-kB in the rescue of multiple myeloma cells from glucocorticoids-induced apoptosis by Bcl-2
78. Bcl-2 antisense therapy in multiple myeloma
79. In vitro treatment with retinoids decreases Bcl-2 protein expression and enhances dexamethasone-induced cytotoxicity and apoptosis in multiple myeloma cells
80. Bcl-x expression in multiple myeloma-possible indicator of chemoresistance
81. Myeloma cell growth arrest, apoptosis, and interleukin 6 receptor modulation induced by EB1089, a vitamin D3 derivative, alone or in association with dexamethasone
82. Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin-6 mediated upregulation of bcl-XL
83. Overexpression of Bcl-x(s), sensitizes MCF-7 cells to chemotherapy-induced apoptosis
84. A recombinant Bcl-x(s) adenovirus selectively induces apoptosis in cancer cells but not in normal bone marrow cells
85. In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene